Cipla Ltd – Strategy, SWOT and Corporate Finance Report

Cipla Ltd – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company

Key Highlights

Cipla Ltd (Cipla) is a pharmaceutical company, which manufactures and distributes branded medicines, generics and active pharmaceutical ingredients (APIs). It offers products for the treatment of various conditions such as cardiovascular and pediatric diseases, dermatological and cosmetological conditions, HIV/AIDS, diabetes, hepatitis, infectious diseases and critical care, malaria, cancer, neurological, ophthalmic, respiratory and urological conditions, osteoporosis and women's health. The company also operates in consumer healthcare and biosimilar businesses. Cipla manufactures metered-dose inhaler devices, spacers and related devices; and conducts R&D to develop new medicines and drug delivery systems. The company has operations in India, US, Canada, South Africa and major regulated and emerging markets among others. Cipla is headquartered in Mumbai, Maharashtra, India.

Scope

Detailed information on Cipla Ltd required for business and competitor intelligence needs

A study of the major internal and external factors affecting Cipla Ltd in the form of a SWOT analysis

An in-depth view of the business model of Cipla Ltd including a breakdown and examination of key business segments

News about Cipla Ltd, such as business expansion, restructuring, and contract wins

Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

Gain understanding of Cipla Ltd and the factors that influence its strategies.

Track strategic initiatives of the company and latest corporate news and actions.

Assess Cipla Ltd as a prospective partner, vendor or supplier.

Support sales activities by understanding your customers' businesses better.

Stay up to date on Cipla Ltds business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Alembic Limited

Dr. Reddy's Laboratories Ltd

Lupin Ltd

Aurobindo Pharma Ltd

Sun Pharmaceutical Industries Ltd

Biocon Ltd

Cadila Healthcare Ltd

Torrent Pharmaceuticals Ltd

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Cipla Ltd - Key Facts

Cipla Ltd - Key Employees

Cipla Ltd - Key Employee Biographies

Cipla Ltd - Major Products and Services

Cipla Ltd - History

Cipla Ltd - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 Company Analysis

Company Overview

Cipla Ltd - Business Description

Business Segment: New Ventures

Overview

Performance

Business Segment: Pharmaceuticals

Overview

Performance

R&D Overview

Cipla Ltd - Corporate Strategy

Cipla Ltd - SWOT Analysis

SWOT Analysis - Overview

Cipla Ltd - Strengths

Cipla Ltd - Weaknesses

Cipla Ltd - Opportunities

Cipla Ltd - Threats

Cipla Ltd - Key Competitors

Section 3 Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 Company’s Lifesciences, Power Financial Deals and Alliances

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Cipla Ltd, Recent Deals Summary

Section 5 Company’s Recent Developments

Jun 21, 2019: Cipla: Resignation of Mr. Peter Lankau as Independent Director of the Company

Jun 10, 2019: Cipla: Closure Of USFDA inspection at Kurkumbh Manufacturing Facility

May 22, 2019: Cipla reports Q4 and FY19 results

May 17, 2019: USFDA post-approval inspection completed at Cipla's Indore manufacturing facility

Apr 22, 2019: Cipla names Dr. Raju Mistry as Global Chief People Officer

Apr 17, 2019: Pulmatrix and Cipla collaborate to develop asthma drug

Mar 31, 2019: Cipla: Product specific pre-approval (PAI) and Good Manufacturing Practices (GMP) inspection at its Kurkumbh plant

Feb 18, 2019: Cipla and Wellthy Therapeutics announce partnership to offer digital therapeutics for diabetes and cardiovascular diseases

Oct 04, 2018: Cipla:Inspection by the United States Food and Drug Administration (USFDA) at the Goa manufacturing facility

Sep 10, 2018: Understanding depression and related symptoms key to suicide prevention in SA

Section 6 Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List of Tables

List of Tables

Cipla Ltd, Key Facts

Cipla Ltd, Key Employees

Cipla Ltd, Key Employee Biographies

Cipla Ltd, Major Products and Services

Cipla Ltd, History

Cipla Ltd, Subsidiaries

Cipla Ltd, Key Competitors

Cipla Ltd, Ratios based on current share price

Cipla Ltd, Annual Ratios

Cipla Ltd, Annual Ratios (Cont…1)

Cipla Ltd, Annual Ratios (Cont…2)

Cipla Ltd, Interim Ratios

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Cipla Ltd, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Cipla Ltd, Performance Chart (2015 – 2019)

Cipla Ltd, Ratio Charts

Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Cipla Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports